Budigalimab

Generic Name: Budigalimab

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 2098225-93-3

Unique Ingredient Identifier: 6VDO4TY3OO

Background: Budigalimab is under investigation in clinical trial NCT04807972 (Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 Is Administered in Combination With IV Modified FOLFIRINOX (Mffx) With or Without IV Budigalimab Compared to Mffx in Adult Participants With Untreated Pancreatic Cancer Metastasis).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)

Phase 2

Recruiting

Conditions: Urothelial Carcinoma

Interventions: Drug: Docetaxel
Drug: Livmoniplimab
Drug: Budigalimab
Drug: Paclitaxel
Drug: Gemcitabine

First Posted Date: 2024-10-09

Last Posted Date: 2025-01-03

Lead Sponsor: AbbVie

Target Recruit Count: 150

Registration Number: NCT06632951

Locations: 🇮🇱
Tel Aviv Sourasky Medical Center /ID# 270106, Tel Aviv, Tel-Aviv, Israel
🇺🇸
Highlands Oncology Group - Springdale /ID# 270290, Springdale, Arkansas, United States
🇮🇱
Rabin Medical Center /ID# 270107, Haifa, Israel

A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Phase 2

Recruiting

Conditions: Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Esophageal Adenocarcinoma

Interventions: Drug: ABBV-400
Drug: Budigalimab
Drug: Fluorouracil
Drug: Oxaliplatin
Drug: Leucovorin

First Posted Date: 2024-10-04

Last Posted Date: 2025-01-07

Lead Sponsor: AbbVie

Target Recruit Count: 180

Registration Number: NCT06628310

Locations: 🇮🇱
Tel Aviv Sourasky Medical Center /ID# 267755, Tel Aviv, Tel-Aviv, Israel
🇺🇸
City of Hope National Medical Center /ID# 268690, Duarte, California, United States
🇺🇸
City of Hope Orange County Lennar Foundation Cancer Center /ID# 272630, Irvine, California, United States

and more 5 locations

A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)

Phase 1

Recruiting

Conditions: Hepatocellular Carcinoma (HCC)

Interventions: Drug: Livmoniplimab
Drug: Budigalimab

First Posted Date: 2024-07-05

Last Posted Date: 2025-01-08

Lead Sponsor: AbbVie

Target Recruit Count: 20

Registration Number: NCT06487559

Locations: 🇨🇳
Beijing Youan Hospital, Capital Medical University -No differernce with previous /ID# 261928, Beijing, Beijing, China
🇨🇳
Mengchao Hepatobiliary Hospital of Fujian Medical University /ID# 262443, Fuzhou, Fujian, China
🇨🇳
Sun Yat-Sen University Cancer Center /ID# 262092, Guangzhou, Guangdong, China

and more 5 locations

Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)

Phase 2

Active, not recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Lenvatinib
Drug: Budigalimab
Drug: Livmoniplimab
Drug: Sorafenib

First Posted Date: 2023-04-21

Last Posted Date: 2025-01-06

Lead Sponsor: AbbVie

Target Recruit Count: 120

Registration Number: NCT05822752

Locations: 🇺🇸
Rocky Mountain Cancer Centers - Denver Midtwon /ID# 254163, Denver, Colorado, United States
🇮🇹
IRCCS AOU di Bologna - Policlinico Sant'Orsola-Malpighi /ID# 253247, Bologna, Emilia-Romagna, Italy
🇺🇸
Arizona Oncology Associates, PC - NAHOA Prescott Valley /ID# 254313, Prescott Valley, Arizona, United States

and more 56 locations

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumors Cancer

Interventions: Drug: Livmoniplimab
Drug: Budigalimab

First Posted Date: 2019-01-30

Last Posted Date: 2025-01-08

Lead Sponsor: AbbVie

Target Recruit Count: 362

Registration Number: NCT03821935

Locations: 🇪🇸
Hospital Clinico Universitario de Valencia /ID# 221107, Valencia, Spain
🇺🇸
University of Washington Medical Center /ID# 268854, Seattle, Washington, United States
🇺🇸
Highlands Oncology Group, PA /ID# 218942, Springdale, Arkansas, United States

and more 51 locations

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy